<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615623</url>
  </required_header>
  <id_info>
    <org_study_id>BT016C</org_study_id>
    <nct_id>NCT05615623</nct_id>
  </id_info>
  <brief_title>Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG</brief_title>
  <official_title>A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of targeted blood brain&#xD;
      barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin&#xD;
      therapy for the treatment of DIPG in pediatric patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single arm, non-randomized feasibility study to evaluate the safety,&#xD;
      feasibility and preliminary efficacy of Blood Brain Barrier Disruption (BBBD) using the&#xD;
      Exablate Type 2 system in pediatric patients with Diffuse Intrinsic Pontine Gliomas (DIPG)&#xD;
      undergoing Doxorubicin chemotherapy. The study will be conducted at a single center in&#xD;
      Canada. Patients will undergo 3 treatment cycles, approximately 4 -6 weeks apart. The study&#xD;
      aims to establish feasibility and safety of Exablate BBBD in conjunction with Doxorubicin in&#xD;
      the treatment of pediatric DIPG and assess preliminary efficacy in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2023</start_date>
  <completion_date type="Anticipated">July 4, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>All adverse events from first treatment to end of study will be documented and reported according to the CTCAE terminology and severity scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Brain Barrier Disruption (BBBD)</measure>
    <time_frame>Immediately post BBBD sonication</time_frame>
    <description>BBBD will be assessed as a comparative ratio measured in pre and post-sonication contrast-enhanced MR images</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor Volume</measure>
    <time_frame>Immediately post BBBD sonication</time_frame>
    <description>Average volume of contrast-enhancement on post sonicated MRI scans will be compared with pre-sonicated scans</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS) and Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale. Tumor related biomarkers will be compared before and after the BBBD procedure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Blood Brain Barrier Disruption (BBBD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exablate</intervention_name>
    <description>Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors</description>
    <arm_group_label>Blood Brain Barrier Disruption (BBBD)</arm_group_label>
    <other_name>Exablate BBBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin infusion</description>
    <arm_group_label>Blood Brain Barrier Disruption (BBBD)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 5 and 18 years, inclusive&#xD;
&#xD;
          -  Patient diagnosed with DIPG&#xD;
&#xD;
          -  At least 4-week and not greater than 12 weeks from completion of radiation therapy&#xD;
&#xD;
          -  Post-radiation imaging does not show evidence of necrosis/ hemorrhage or other&#xD;
             features that contraindicate MRgFUS&#xD;
&#xD;
          -  Able to attend all study visits and with life expectancy of at least 6 months&#xD;
&#xD;
          -  Able and willing to give consent and/or assent or have a legal guardian who is able&#xD;
             and willing to do so&#xD;
&#xD;
          -  If on steroids, stable or decreasing dose for at least 7 days prior to study entry&#xD;
&#xD;
          -  If brain surgery occurred, at least 14 days passed since last brain surgery and the&#xD;
             patient is fully recovered and neurologically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of cranial or systemic infection&#xD;
&#xD;
          -  Known life-threatening systemic disease&#xD;
&#xD;
          -  Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin,&#xD;
             idarubicin, and/or other anthracyclines and anthracenediones&#xD;
&#xD;
          -  Contraindication to Doxorubicin. - Known sensitivity to DEFINITYÂ® ultrasound contrast&#xD;
             agent or known hypersensitivity to perflutren microsphere or its components, e.g.,&#xD;
             polyethylene glycol. - Known sensitivity to gadolinium-based contrast agents&#xD;
&#xD;
          -  Active seizure disorder or epilepsy (seizures despite medical treatment) for a minimum&#xD;
             of 4 weeks prior to first cycle/Exablate BBBD procedure captured by history&#xD;
&#xD;
          -  Patients with positive HIV status. - Immunosuppression (corticosteroids to&#xD;
             prevent/treat brain edema are permitted)&#xD;
&#xD;
          -  Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular&#xD;
             malformation, cerebral aneurysm, or vasculitis&#xD;
&#xD;
          -  Hypertension per age&#xD;
&#xD;
          -  History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour&#xD;
             hemorrhage&#xD;
&#xD;
          -  Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g.,&#xD;
             ASA, non-steroidal anti-inflammatory drugs [NSAIDs], statins) within washout period&#xD;
             prior to treatment&#xD;
&#xD;
          -  Patient receiving bevacizumab (Avastin) therapy or increasing doses of steroids&#xD;
&#xD;
          -  Symptoms and signs of increased intracranial pressure&#xD;
&#xD;
          -  Previous participation in other chemotherapy, molecularly targeted therapy or&#xD;
             immunotherapy treatment-related phase 1 or 2 trials&#xD;
&#xD;
          -  Tumor not visible on any pre-therapy or post-radiation imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nadir Alikacem</last_name>
    <phone>+12146302000</phone>
    <email>nadira@insightec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Rutka, MD</last_name>
      <phone>416-813-6425</phone>
      <email>james.rutka@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Maheleth Llinas</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>2476</phone_ext>
      <email>maheleth.llinas@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Nir Lipsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Rutka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>January 5, 2023</last_update_submitted>
  <last_update_submitted_qc>January 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DIPG</keyword>
  <keyword>Focused Utrasound</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Phase I trial</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

